T Cell

PHILADELPHIA — Upcoming T-cell therapies may treat antiphospholipid syndrome and other autoimmune diseases without compromising a patient’s defenses against infection, according to data presented at ACR Convergence 2022.

The FDA granted fast track designation to MT-101, an investigational chimeric antigen receptor monocyte, for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Researchers have discovered a link between neurotoxicity related to chimeric antigen receptor T-cell therapy and development of subsequent hypophosphatemia.

The FDA granted regenerative medicine advanced therapy designation to CTX130, a chimeric antigen receptor T-cell therapy under development for the treatment of mycosis fungoides and Sézary syndrome.

In this video, Amrita Krishnan, MD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope Cancer Center, discusses major developments in multiple myeloma presented at ASCO Annual Meeting.

CLEVELAND — Cutaneous T-cell lymphomas can often have different manifestations in the skin, according to Kevin D. Cooper, MD, chair of dermatology at Case Western Reserve University School of Medicine.

Children with an inflammatory syndrome linked to SARS-CoV-2 infection mount a normal T-cell response to the virus, according results from a multi-institutional study ­­reported in the European Journal of Immunology.

T-cell testing was nearly twice as sensitive at identifying early Lyme disease compared with the standard two-tiered serologic testing and more than three times more sensitive in the first 4 days, researchers reported at IDWeek.

Researchers successfully created a CAR T-cell construct to signal CD58 mutation or loss in patients with large B cell lymphomas, according to a presentation from the ASH Annual Meeting and Exposition.

The FDA has cleared an investigational new drug application for T-cell therapy to treat high-risk patients with COVID-19. It was the top story in hematology/oncology last week.